Loading
Life sciences · Journal article
BMC Endocrine Disorders · October 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Polyendocrine metabolic ovarian syndrome (PMOS; formerly polycystic ovary syndrome [PCOS]) is the most common endocrinopathy in reproductive-age women. Whether lean (BMI < 25 kg/m²) and overweight/obese (BMI ≥ 25 kg/m²) phenotypes carry materially different long-term metabolic and reproductive risks remains incompletely defined, particularly in Chinese women. The objective of this study was to compare long-term metabolic and reproductive outcomes between lean and overweight/obese PMOS phenotypes in Chinese women. We conducted a retrospective cohort study of 1 500 women (500 lean; 1 000 overweight/obese) with Rotterdam-defined PMOS enrolled between December 2020 and May 2022 at a tertiary reproductive medicine centre and followed through December 2025 (median follow-up, 4.3 years). Dual primary endpoints were incident metabolic syndrome (MetS; Chinese Diabetes Society 2017 criteria) and cumulative live-birth rate (CLBR) in the assisted reproductive technology (ART) subgroup. Analyses used Cox proportional-hazards regression, generalised estimating equations (GEE), and patient-level logistic regression. Sensitivity analyses included propensity-score matching, overlap weighting, and alternative MetS definitions. At baseline, overweight/obese women had higher BMI (29.54 ± 3.04 vs. 22.23 ± 1.50 kg/m²), higher HOMA-IR (3.90 ± 1.50 vs. 2.20 ± 0.82), and higher prevalent MetS (31.8% vs. 0.2%). Incident MetS occurred in 19.94% vs. 9.22% of lean women (adjusted hazard ratio 2.33, 95% CI 1.66–3.27; P < 0.001); incident type 2 diabetes in 7.0% vs. 2.6% ( P = 0.001). Among 973 ART patients (1 432 cycles), CLBR was 52.84% vs. 70.49% (adjusted odds ratio [aOR] 0.46, 95% CI 0.34–0.62; P < 0.001); cycle-level GEE yielded an aOR of 0.56 (95% CI 0.44–0.70). Gestational diabetes (23.49% vs. 10.06%), hypertensive disorders of pregnancy (9.44% vs. 2.83%), and macrosomia (11.65% vs. 4.40%) were all more frequent in the overweight/obese group (all P ≤ 0.001). Subgroup estimates were consistent across age, Rotterdam phenotype, and baseline insulin-resistance status. Elevated BMI in PMOS was associated with a more than two-fold risk of incident MetS and an approximately halved CLBR after ART, alongside a substantially higher burden of pregnancy complications. Lean PMOS was not metabolically benign. These findings support BMI-stratified metabolic surveillance and structured pre-conception weight management in routine PMOS care. Not applicable.